Abstract

A REVIEW ON BRAIN TARGETED DRUG DELIVERY SYSTEM

Gatisha Jadhav*, Ashok Rabade, Aishwarya Khope, Tejas Waje and Mayur Mane

ABSTRACT

According to the overall prevalence rate for CNS pathology, roughly 1.5 billion people suffer from central nervous system problems. The presence of the blood brain barrier, which has a tendency to hinder drug distribution and denotes the greatest hindrance to the creation of new medications, is the most worrisome truth regarding drug delivery to the CNS. The brain is a sensitive organ that has been well- protected by nature. The technique and procedure for delivering a medicine into the brain or central nervous system is known as brain-targeted drug delivery. The main issue arises during brain targeting in the event of a variety of brain diseases and disorders, including Parkinson Alzheimer, Epilepsy. Only highly lipophilic compounds can pass through the blood brain barrier and the blood cerebrospinal fluid barrier, Poor delivery strategies that do not penetrate the resistant BBB are commonly blamed for the clinical failure. It prevents many medications from passively diffusing into the brain and is a substantial impediment to the pharmacological therapy of central nervous system disorders. Non-invasive methods which includes transformation into lipophilic analogues, prodrugs, chemical drug, which uses the olfactory and trigeminal neuronal pathways to deliver drugs to the brain. Invasive approaches, on the other hand, that rely on osmotic or biochemical disruption of the BBB, or direct intracranial drug delivery by, intracerebral, or intrathecal administration after generating reversible apertures in the brain, are recognised. This review encompasses detailed discussion of some of the recent drug delivery systems like Dendrimers, Lipoplexes, Polyplexes, Scaffolds.

Keywords: Dendrimers, Polyanhydrides, Lipoplexes, Polyplexes, Scaffolds, Modified nanoparticles.